Market Cap 23.60B
Revenue (ttm) 3.18B
Net Income (ttm) 1.33B
EPS (ttm) N/A
PE Ratio 20.20
Forward PE 20.55
Profit Margin 41.94%
Debt to Equity Ratio 0.00
Volume 534,300
Avg Vol 502,254
Day's Range N/A - N/A
Shares Out 42.45M
Stochastic %K 89%
Beta 0.58
Analysts Strong Sell
Price Target $667.36

Company Profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated wit...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 301 608 9292
Address:
1000 Spring Street, Silver Spring, United States
AXLFI_HQ
AXLFI_HQ Jul. 4 at 12:44 PM
The most recent Momentum signal on $UTHR triggered on 2026-07-02. The expected return for the selected horizon is +12.64% with a historical profit probability of +70.21%. Learn more: https://axlfi.com/factor-analysis?symbol=UTHR&factor=momentum&timeframe=daily
0 · Reply
kcphaeton
kcphaeton Jul. 2 at 5:09 PM
$MNKD $UTHR @Wolf1971 sometimes a girl needs to get her panties in a wad. Right Martine? Don’t get them in a wad.
1 · Reply
notreload_ai
notreload_ai Jul. 2 at 1:01 PM
$UTHR has acquired Thymmune Therapeutics in a $140M upfront + $160M milestone deal to advance thymus-derived cell therapies for immune disorders and organ transplantation. https://notreload.xyz/xy/united-therapeutics-acquires-thymmune-for-300m/
0 · Reply
LandonCapital
LandonCapital Jul. 2 at 12:13 PM
$UTHR https://landoncapital.net/strength-in-numbers-united-therapeutics-acquires-thymmune-for-up-to-300m/
0 · Reply
Outcomes
Outcomes Jul. 2 at 10:40 AM
$IBRX $MNKD $UTHR ......Thymus.......the 'T' in T-cell! '.......thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases.' 'The clinical proof of concept and further development of THY-100 has the potential to broaden thymic regenerative medicine approaches for transplant tolerance, serious immune-mediated diseases, and enhanced longevity for older adults with diminished T-cell function.' PSS knows. Martine knows.
3 · Reply
Outcomes
Outcomes Jul. 2 at 10:37 AM
$MNKD $UTHR https://ir.unither.com/press-releases/2026/07-02-2026-113022825
0 · Reply
txbondman
txbondman Jun. 30 at 6:36 PM
bot $DVN, $HLI, $IDXX, $TKO, and $UTHR to double down; (Don't try this at home!!)
0 · Reply
JFais
JFais Jun. 30 at 2:31 PM
$LQDA actually comes to mind here after judge ruling (barring any left field scenarios) $INSM $UTHR longs bashing & doing best to bring it down, but Yutrepia's tolerability leading to increased efficacy speaks for itself
0 · Reply
prismmarketview
prismmarketview Jun. 29 at 6:06 PM
$UTHR is building an under‑the‑radar moat in lung transplants. Its FDA‑approved lung perfusion platform can turn more “marginal” lungs into usable grafts and plug UT directly into the transplant workflow. #UTHR #lungtransplant #medtech #biotech https://prismmarketview.com/united-therapeutics-builds-a-moat-around-lung-transplants/
0 · Reply
Outcomes
Outcomes Jun. 29 at 10:51 AM
$UTHR $MNKD https://ir.unither.com/press-releases/2026/06-29-2026-113020795
0 · Reply
Latest News on UTHR
United Therapeutics acquires Thymmune Therapeutics

2026-07-02T10:35:12.000Z - 2 days ago

United Therapeutics acquires Thymmune Therapeutics


United Therapeutics Transcript: AGM 2026

Jun 26, 2026, 10:30 AM EDT - 8 days ago

United Therapeutics Transcript: AGM 2026


United Therapeutics says TETON-1 study published in NEJM

2026-05-18T20:21:29.000Z - 6 weeks ago

United Therapeutics says TETON-1 study published in NEJM


United Therapeutics reports Q1 EPS $5.82, consensus $6.86

2026-05-07T09:22:42.000Z - 2 months ago

United Therapeutics reports Q1 EPS $5.82, consensus $6.86


United Therapeutics reports Q1 EPS $5.82, consensus $6.86

2026-05-07T09:21:34.000Z - 2 months ago

United Therapeutics reports Q1 EPS $5.82, consensus $6.86


United Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 9:00 AM EDT - 2 months ago

United Therapeutics Earnings Call Transcript: Q1 2026


United Therapeutics Quarterly report: Q1 2026

May 6, 2026, 9:00 AM EDT - 2 months ago

United Therapeutics Quarterly report: Q1 2026


United Therapeutics Earnings release: Q1 2026

May 6, 2026, 9:00 AM EDT - 2 months ago

United Therapeutics Earnings release: Q1 2026


United Therapeutics Slides: Q1 2026

May 6, 2026, 9:00 AM EDT - 2 months ago

United Therapeutics Slides: Q1 2026


United Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

United Therapeutics Proxy statement: Proxy filing


United Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

United Therapeutics Proxy statement: Proxy filing


United Therapeutics Transcript: Study result

Mar 2, 2026, 8:30 AM EST - 4 months ago

United Therapeutics Transcript: Study result


United Therapeutics Press release: Study result

Mar 2, 2026, 8:30 AM EST - 4 months ago

United Therapeutics Press release: Study result


United Therapeutics Slides: Study result

Mar 2, 2026, 8:30 AM EST - 4 months ago

United Therapeutics Slides: Study result


United Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 9:00 AM EST - 4 months ago

United Therapeutics Earnings Call Transcript: Q4 2025


United Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 9:00 AM EST - 4 months ago

United Therapeutics Earnings release: Q4 2025


United Therapeutics Annual report: Q4 2025

Feb 25, 2026, 9:00 AM EST - 4 months ago

United Therapeutics Annual report: Q4 2025


United Therapeutics Slides: Q4 2025

Feb 25, 2026, 9:00 AM EST - 4 months ago

United Therapeutics Slides: Q4 2025


Flurry of Bullish Inflows Sends United Therapeutics Higher

Dec 3, 2025, 7:19 AM EST - 7 months ago

Flurry of Bullish Inflows Sends United Therapeutics Higher


United Therapeutics Earnings Call Transcript: Q3 2025

Oct 29, 2025, 9:00 AM EDT - 8 months ago

United Therapeutics Earnings Call Transcript: Q3 2025


United Therapeutics Earnings release: Q3 2025

Oct 29, 2025, 9:00 AM EDT - 8 months ago

United Therapeutics Earnings release: Q3 2025


United Therapeutics Quarterly report: Q3 2025

Oct 29, 2025, 9:00 AM EDT - 8 months ago

United Therapeutics Quarterly report: Q3 2025


United Therapeutics Slides: Q3 2025

Oct 29, 2025, 9:00 AM EDT - 8 months ago

United Therapeutics Slides: Q3 2025


United Therapeutics Transcript: Study Update

Sep 28, 2025, 12:30 PM EDT - 9 months ago

United Therapeutics Transcript: Study Update


United Therapeutics Press release: Study Update

Sep 28, 2025, 12:30 PM EDT - 9 months ago

United Therapeutics Press release: Study Update


United Therapeutics Slides: Study Update

Sep 28, 2025, 12:30 PM EDT - 9 months ago

United Therapeutics Slides: Study Update


United Therapeutics: Is UTHR Stock Still A Buy At $400?

Sep 3, 2025, 10:10 AM EDT - 10 months ago

United Therapeutics: Is UTHR Stock Still A Buy At $400?


United Therapeutics Earnings Call Transcript: Q2 2025

Jul 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings Call Transcript: Q2 2025


United Therapeutics Quarterly report: Q2 2025

Jul 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Quarterly report: Q2 2025


United Therapeutics Earnings release: Q2 2025

Jul 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings release: Q2 2025


United Therapeutics Slides: Q2 2025

Jul 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Slides: Q2 2025


United Therapeutics Earnings Call Transcript: Q1 2025

Apr 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings Call Transcript: Q1 2025


United Therapeutics Earnings release: Q1 2025

Apr 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings release: Q1 2025


United Therapeutics Quarterly report: Q1 2025

Apr 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Quarterly report: Q1 2025


United Therapeutics Slides: Q1 2025

Apr 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Slides: Q1 2025


United Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

United Therapeutics Proxy statement: Proxy Filing


United Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

United Therapeutics Proxy statement: Proxy Filing


AXLFI_HQ
AXLFI_HQ Jul. 4 at 12:44 PM
The most recent Momentum signal on $UTHR triggered on 2026-07-02. The expected return for the selected horizon is +12.64% with a historical profit probability of +70.21%. Learn more: https://axlfi.com/factor-analysis?symbol=UTHR&factor=momentum&timeframe=daily
0 · Reply
kcphaeton
kcphaeton Jul. 2 at 5:09 PM
$MNKD $UTHR @Wolf1971 sometimes a girl needs to get her panties in a wad. Right Martine? Don’t get them in a wad.
1 · Reply
notreload_ai
notreload_ai Jul. 2 at 1:01 PM
$UTHR has acquired Thymmune Therapeutics in a $140M upfront + $160M milestone deal to advance thymus-derived cell therapies for immune disorders and organ transplantation. https://notreload.xyz/xy/united-therapeutics-acquires-thymmune-for-300m/
0 · Reply
LandonCapital
LandonCapital Jul. 2 at 12:13 PM
$UTHR https://landoncapital.net/strength-in-numbers-united-therapeutics-acquires-thymmune-for-up-to-300m/
0 · Reply
Outcomes
Outcomes Jul. 2 at 10:40 AM
$IBRX $MNKD $UTHR ......Thymus.......the 'T' in T-cell! '.......thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases.' 'The clinical proof of concept and further development of THY-100 has the potential to broaden thymic regenerative medicine approaches for transplant tolerance, serious immune-mediated diseases, and enhanced longevity for older adults with diminished T-cell function.' PSS knows. Martine knows.
3 · Reply
Outcomes
Outcomes Jul. 2 at 10:37 AM
$MNKD $UTHR https://ir.unither.com/press-releases/2026/07-02-2026-113022825
0 · Reply
txbondman
txbondman Jun. 30 at 6:36 PM
bot $DVN, $HLI, $IDXX, $TKO, and $UTHR to double down; (Don't try this at home!!)
0 · Reply
JFais
JFais Jun. 30 at 2:31 PM
$LQDA actually comes to mind here after judge ruling (barring any left field scenarios) $INSM $UTHR longs bashing & doing best to bring it down, but Yutrepia's tolerability leading to increased efficacy speaks for itself
0 · Reply
prismmarketview
prismmarketview Jun. 29 at 6:06 PM
$UTHR is building an under‑the‑radar moat in lung transplants. Its FDA‑approved lung perfusion platform can turn more “marginal” lungs into usable grafts and plug UT directly into the transplant workflow. #UTHR #lungtransplant #medtech #biotech https://prismmarketview.com/united-therapeutics-builds-a-moat-around-lung-transplants/
0 · Reply
Outcomes
Outcomes Jun. 29 at 10:51 AM
$UTHR $MNKD https://ir.unither.com/press-releases/2026/06-29-2026-113020795
0 · Reply
grampslol
grampslol Jun. 28 at 4:35 PM
$MNKD betcha $UTHR is working on a relinepeg SMI... they're working on the dpi " category killer" to use martine's phrase already for tyvaso dpi because dpi has coughing issues according to the uthr ceo ... don't get clanned listening to lying pumpers... #afizzle #dilutioncompany #800millionauthorizedsheres #poorclan
2 · Reply
clan
clan Jun. 28 at 3:40 PM
$MNKD Don't take advise from those who were whining, cackling, and complaining back when CEO Lasagna's family were loading up on Mannkind shares, just a couple months ago. FDA approval is incoming. #countdown $UTHR #ralinepegdpi #tyvasodpi #afrezza #furoscix #vgo $SPY
1 · Reply
clan
clan Jun. 27 at 11:19 PM
$MNKD Afrezza commercials incoming!📺 Bring back the Ice Cream truck🍦 and the weiner dog pulling a cart full of bunned weiners🌭. Keep the pooch🐶, but get new actors. # decending salads🥗 Co-brand commercial? Furoscix/Afrezza? Hmm? Where are the Tyvaso DPI commercials, $UTHR ?
2 · Reply
marconaki
marconaki Jun. 27 at 3:01 PM
$UTHR Many institutions have been selling some of their AI winners and biotech has been benefiting from those proceeds. UTHR has been one of the beneficiaries and many active managers have been accumulating. It has strong cash flow, highly profitable franchise, and leadership in pig organ and organ growing research. This makes it a very strong candidate for acquisition. Top likely buyers: Merck or J&J Merck needs the cash flow and profitable franchise due to a patent cliff. J&J would benefit from a strategic portfolio synergy aspect. UTHR will do well with or without being acquired, this could be $1000 in 12-18 months.
0 · Reply
AcceleratorModel
AcceleratorModel Jun. 26 at 7:30 AM
$UTHR looks like it should move soon. Trend says ⬆️
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 25 at 8:10 PM
$UTHR Current Stock Price: $543.55 Contracts to trade: $540.0 UTHR Jul 17 2026 Call Entry: $18.00 Exit: $29.91 ROI: 66% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
G101SPM
G101SPM Jun. 25 at 7:39 PM
#SHOWTIME European Academy of Neurology Congress (June 26) Scheduled to appear: $IMUX, $OCS United Therapeutics Corporation Annual General Meeting (June 26) Scheduled to appear: $UTHR Aon Plc Class A Annual General Meeting (June 26) Scheduled to appear: $AON
0 · Reply
Bazziggr
Bazziggr Jun. 25 at 3:00 PM
$UTHR BSX
0 · Reply
JustAnotherAffizle
JustAnotherAffizle Jun. 25 at 1:38 PM
0 · Reply
grampslol
grampslol Jun. 25 at 12:15 PM
Poor $MNKD pumper @clan 👀 deluding himself as he tries to deceive the naive $SPY $UTHR 👀 about the afizzle permapenny company.... an upside down 🤡
0 · Reply
grampslol
grampslol Jun. 24 at 5:09 PM
$MNKD thanks @kevinmik , I don't expect them to be working behind the scenes except perhaps if they're not working ahead on the next dilution since they are top heavy, have no pipeline funds and have a major flop with their flagship afrezza dpi approved in 2014 ... oh, yeah almost forgot about what the $UTHR ceo martine said about the tyvaso dpi coughing problems and how they have a category killer with their new Soft Mist Inhalation technology...
0 · Reply
clan
clan Jun. 24 at 3:16 PM
$MNKD Smart investors look to the future. Mannkind's future is bright. Incoming FDA approval - Readyflow. Advancing trials. Expanding pipeline. Growing Revenues. Helping patients. Life more humann. More green coming. Big green. $UTHR $BX
1 · Reply